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Aims: The purpose of this study was to evaluate adherence to insulin therapy in patients
with  diabetes. The underlying factors affecting insulin injection omission among patients
with  type 1 or 2 diabetes were also investigated.
Methods: This cross-sectional study has been conducted on 507 patients with diabetes.
Adherence to insulin therapy was measured by the 8-Item Moriskey Medication Adherence
Scale (MMS) and the autocompliance method. Furthermore, socio-demographic, disease and
injection-related barriers to insulin injection were assessed.
Results: Based on the Morisky Green test, 14.3% and 28.8% of patients with type 1 and 2 dia-
betes respectively had low adherence to insulin therapy. However, almost all patients were
adherent according to the autocompliance method. Different factors showed a signiﬁcant
association with insulin compliance in both groups.
Conclusions: The current study suggests acceptable adherence to insulin therapy among
patients with type 1, and poor adherence in patients with type 2, diabetes. Our ﬁndingsregarding barriers with signiﬁcant effect on insulin adherence may be useful to identify
patients at risk for low compliance, and to guide the design of proper strategies to improve
adherence and the consequential clinical outcomes.
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1.  Introduction
The increasing number of patients with diabetes is costly and
has a large economic burden on society, so the care and man-
agement of patients with insulin treatment has seen a rapid
evolution, contributing to improved metabolic control and
delayed progression of microvascular complications in these
patients [1–4]. Also, clinical outcomes support beneﬁts associ-
ated with early initiation and intensiﬁcation of insulin therapy
in patients with type 2 diabetes [5].
However, medications are effective only when they have
been taken according to the recommendations of health care
providers and unfortunately poor adherence among patients
with diabetes remains a common problem [6,7].
The centers for disease control and prevention (CDC) esti-
mates that more  than 25% of patients with diabetes take
insulin. In spite of the crucial role of adherence to insulin
for achieving therapeutic goals, few studies have evaluated
adherence to insulin and its associated factors.
In a study using an internet survey of 502 U.S. adults with
type 1 or type 2 diabetes, more  than half of them reported
intentional insulin omission [8]. Another study revealed that
77% of the prescribed insulin dose was taken by patients [9].
A systematic review in 2004 disclosed that only one-third of
the prescribed insulin dose was used by young patients and
estimated adherence was 62–64% among patients with type 2
diabetes.
Low insulin adherence reported in previous studies may
be the culprit for the unstable and generally poor glycemic
control [10]. Therefore, identiﬁcation of the underlying factors
which predispose patients to poor adherence is necessary for
better glycemic control.
Several studies have been conducted to detect factors asso-
ciated with insulin adherence, but there is lack of evidence
regarding the inﬂuence of these factors on adherence to
insulin [8,11,12]. In addition there is scarce information about
the rate of poor adherence to insulin therapy and related risk
factors in developing countries which play a fundamental role
in achievement and maintenance of adequate glycemic con-
trol [11,13,14].
Therefore, the present study was designed to evaluate
adherence to insulin therapy in patients with diabetes. The
secondary goal of the study was to investigate the underlying
factors that may predispose patients to low insulin adherence.
2.  Methods
In this cross-sectional study 507 patient with type 1 (n = 251)
or type 2 (n = 256) diabetes were selected using the conve-
nience sampling method from Endocrinology and Metabolism
Research Center (EMRC) outpatient diabetes clinic, afﬁliated to
Tehran University of Medical Sciences (TUMS).
Participants had to be on a stable dose of insulin prior to
the study and willing to participate in the study. Patients whoPlease cite this article in press as: S. Farsaei, et al., Insulin adherence in p
Diab. (2014), http://dx.doi.org/10.1016/j.pcd.2014.03.001
had cognitive impairment or a severe health condition, who
could not participate in the study, were excluded.
A questionnaire was designed to collect information about
socio-demographic characteristics (age, sex, BMI, level ofx x x ( 2 0 1 4 ) xxx–xxx
education), type and duration of diabetes and insulin injec-
tion, adherence to insulin and barriers to patient compliance.
Adherence to insulin was measured by the 8-Item Moriskey
Medication Adherence Scale (MMAS) reported by Sakthong
et al. According to 8-Item MMAS, a patient was considered
a low adherent if s/he received scores of less than 6.0, while
scores between 6.0 to <8.0 and 8.0 were categorized as medium
and high adherence respectively [1].
Furthermore, compliance with insulin was also measured
by the autocompliance method. The autocompliance test esti-
mates the number of skipped insulin injections during the
previous month, following the methodology of Haynes et al.
[15]. It measures according to patient self reporting of difﬁ-
culty in taking the medication by asking two  open questions:
(1) “Did you have any difﬁculties in insulin injection?” and (2)
“How many  times did you skip insulin injection in the last
month?”
Autocompliance was calculated by using the following for-
mula:
Total number of insulin injections
Total number of prescribed insulin injection
× 100
Patients who afﬁrmed taking more  than 80% of the total
number of prescribed insulin injections were considered as
compliers with insulin [16].
Barriers to insulin injection were assessed in the last
section of the questionnaire which covered patient and med-
ication factors.
Validity and reliability of the questionnaire was determined
in a pilot study.
A pharmacist assessed adherence to insulin and its
associated factors via telephone interview, using the ﬁnal
questionnaire.
The TUMS ethic committee approved the study protocol
and verbal informed consent was obtained from participants
prior to the interview.
2.1.  Statistical  analysis
The distribution of continuous variables was assessed by the
Kolmogrov–Smirnov test. Continuous variables are expressed
as mean ± SD and categorical data are expressed as a per-
centage. The chi square test was used to analyze categorical
data. The association between level of adherence and contin-
uous variables was assessed by independent sample T-test
for parametric variables and Mann–Whitney U-test for non-
parametric variables. A P-value less than 0.05 was considered
as statistically signiﬁcant. Analysis was done with SPSS ver-
sion 11.5 software.
3.  Results
Almost half of the studied population (49.4%, n = 251) wereatients with diabetes: Risk factors for injection omission, Prim. Care
patients with type 1 diabetes. Demographic variables and dia-
betes characteristics of the participants are shown in Table 1.
Cronbach’s alpha coefﬁcient was 0.82, conﬁrming the reli-
ability of the questionnaire.
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Table 1 – Demographic variables and diabetes characteristics of participants.
Total (n = 508) Type 1 (n = 251) Type 2 (n = 257)
Socio-demographic characteristics
Age, yearsa 38.2 (2.0) 20.6 (9.9) 55.3 (11.5)
Educational statusb
Student 136 (26.9) 136 (54.8) 0 (0.0)
Illiterate 55 (10.9) 0 (0.0) 55 (21.4)
Under diploma 154 (30.5) 26 (10.5) 128 (49.8)
Diploma 102 (20.2) 47 (19.0) 55 (21.4)
University 58 (11.5) 39 (15.7) 19 (7.4)
Sex, maleb 217 (42.7) 128 (51.0) 89 (34.6)
BMI, kg/m2 a 24.7 (5.7) 21.5 (4.5) 27.9 (4.8)
Diabetes characteristics
Duration of diabetes, yearsa 11.2 (8.2) 8.3 (7.3) 14.0 (8.1)
Duration of insulin injection, yearsa 6.1 (6.3) 8.1 (7.2) 4.2 (4.6)
Insulin daily dose, unita 48.5 (26.6) 44.7 (24.5) 52.3 (28.0)
Number of daily injectionsb
1 41 (8.0) 13 (5.2) 28  (10.9)
2 330 (65.0) 149 (59.4) 181  (70.4)
≥3 137 (27.0) 89 (35.5) 48 (18.7)
Injection deviceb
Syringe 462 (90.9) 228 (90.8) 234 (91.1)
Pen 46 (9.1) 23 (9.2) 23 (8.9)
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b Categorical variables are expressed as n (%).
.1.  Adherence  to  insulin  injection
ased on the Morisky Green test, 22.3% of patients with type 1
iabetes had high adherence, while 63.4% and 14.3% of them
ad medium and low adherence respectively. In patients with
ype 2 diabetes, 24.9% were highly adherent to insulin injec-
ions whereas, 46.3% and 28.8% of them were considered to
ave medium and low adherence to insulin therapy. There
as a signiﬁcant difference regarding patients with low com-
liance in these two study groups (P < 0.01).
According to the autocompliance method, almost all
atients (99.4%) of the studied population were compliant with
nsulin injections and only two patients were non-compliant.
.2.  Barriers  to  insulin  injection
ossible factors inﬂuencing patient’s adherence to insulin
njection are illustrated in Table 2.
In patients with type 1 diabetes, insulin injection by the
atient’s care giver was more  common than patients with type
 diabetes (P = 0.03). Furthermore the number of daily insulin
njections in this group was signiﬁcantly higher than patients
ith type 2 diabetes (P < 0.01).
In patients with type 1 diabetes, older patients (23.9 ± 9.4
ears old) injected insulin themselves compared to younger
atients (13.5 ± 6.9 years old) who needed care givers for
nsulin injections (P = 0.03). However, caregivers of older adults
62.5 ± 11.5 years old) with type 2 diabetes injected insulin for
hem in comparison with younger patients (53.2 ± 10.6 years
ld) who  could inject insulin themselves (P = 0.25).
Patient complaints regarding interference of insulin injec-Please cite this article in press as: S. Farsaei, et al., Insulin adherence in p
Diab. (2014), http://dx.doi.org/10.1016/j.pcd.2014.03.001
ion with physical and daily activities and meal plans was
igniﬁcantly more  common in patients with type 2 diabetes
P ≤ 0.01). There was more  frequent complaint of injection site
eactions in patients with type 2 diabetes than type 1 (P = 0.03),but on the other hand patients with type 1 diabetes experi-
enced more  embarrassment with insulin injections (P < 0.01).
Patients with type 2 diabetes more  commonly forget about
insulin injections than patients with type 1 diabetes (P < 0.01),
and also a greater number of type 2 patients believed that
insulin injection have a negative effect on their overall health
than patients with type 1 diabetes (P < 0.01). More  patients with
type 2 diabetes reported insulin omission because of illness
than type 1 patients (P < 0.01). Taking multiple daily medi-
cations was another factor contributing to skipped insulin
injections with higher frequency in patients with type 2 dia-
betes (P < 0.01). In addition, patients with type 2 diabetes were
more concerned about weight gain than patients with type 1
diabetes (P = 0.04).
3.3.  Association  between  patients’  adherence  to
insulin  injection  and  independent  factors
Association between adherence to insulin injection based on
the MMAS method in patients with type 1 and 2 diabetes and
potential barriers are shown in Tables 3 and 4.
Factors that showed a signiﬁcant association with insulin
compliance in both groups were: being a time consuming
process; embarrassment; feeling worse after injections; for-
getfulness; sick days; experience of hypoglycemia; medication
cost; weight gain; insulin shortage; and difﬁculties in prepar-
ing injection.
In patients with type 1 diabetes there was a signiﬁcant
inverse correlation between insulin compliance and BMI  while
a signiﬁcant correlation with lack of enough injection instruc-
tions or injection site pain was only noted in patients withatients with diabetes: Risk factors for injection omission, Prim. Care
type 2 diabetes.
Although patients who were considered adherent accord-
ing to MMS had a better compliance to physical activities, the
difference was only signiﬁcant in patients with type 1 diabetes
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Table 2 – Distribution of possible barriers to insulin adherence in patients with type 1 and type 2 diabetes.
Barrier Total (n = 508) Type 1 (n = 251) Type 2 (n = 257) P-value
Injection device 1.00
Syringe 462 (90.9) 228 (90.8) 234 (91.1)
Pen 46 (9.1) 23 (9.2) 23 (8.9)
Incapability for self injection 138 (27.2) 79 (31.5) 59 (23.0) 0.03
Number of daily injections
1 41 (8.0) 13 (5.2) 28 (10.9) <0.01
2 330 (65.0) 149 (59.4) 181 (70.4)
≥3 137 (27.0) 89 (35.4) 48 (18.7)
Interference with
Usual daily activities 99 (19.5) 38 (15.1) 61 (23.7) 0.01
Meal planning 136 (26.8) 53 (21.1) 83 (32.2) <0.01
Physical activities 313 (61.6) 120 (47.8) 200 (78.1) <0.01
Being time consuming 321 (63.2) 233 (92.8) 224 (87.5) 0.12
Difﬁcult to inject 187 (36.8) 228 (90.8) 215 (84.0) 0.06
Injection site pain 100 (19.7) 176 (70.1) 188 (73.4) 0.69
Injection site reactions 458 (90.2) 120 (47.8) 148 (57.8) 0.03
Weight gain 12 (2.4) 2 (0.8) 10 (3.9) 0.04
Embarrassment 137 (27.0) 122 (48.6) 68 (26.5) <0.01
Fear of hypoglycemia 444 (87.4) 198 (78.9) 224 (87.2) 0.53
Forgetfulness 53 (10.4) 17 (6.8) 36 (14.0) <0.01
Belief in negative effects of insulin
on overall health
129  (25.4) 46 (18.3) 83 (32.3) <0.01
Lack of enough injection
instructions
306 (59.6) 152 (60.6) 154 (59.9) 0.89
Feeling worse after insulin
injection
24 (4.7) 6 (2.4) 18 (7) 0.02
Polypharmacy 31 (6.1) 7 (2.8) 24 (9.3) <0.01
Sick days 61 (12.0) 18 (7.2) 43 (16.7) <0.01
Cost 13 (2.6) 6 (2.4) 7 (2.7) 1.00
Insulin shortage 15 (3.0) 
Variables are expressed as n (%).
(P = 0.02). On the other hand, patients adherent to insulin ther-
apy also had a better compliance to medical nutrition therapy
and this difference was only signiﬁcant among patients with
type 2 diabetes (P = 0.02). Moreover, persistence with insulin
therapy was more  common among adherent patients with
both type 1 and type 2 diabetes (P = 0.02 and P < 0.01 respec-
tively).
4.  Discussion
In spite of the importance of adherence to insulin for achieving
therapeutic goals, there is lack of evidence about the rate of
adherence to insulin therapy and associated risk factors.
Current study revealed that according to the Morisky Green
test, 85.7% of patients with type 1 diabetes and 71.2% of
patients with type 2 diabetes had intermediate to high adher-
ence. Higher adherence in patients with type 1 diabetes may
be related to the understanding of these patients about the
more crucial role of insulin injection for glycemic control and
a higher possibility of life threatening events as a result of
insulin omission compared to patients with type 2 diabetes
who  have residual insulin secretions.
Unexpectedly, based on the autocompliance methodPlease cite this article in press as: S. Farsaei, et al., Insulin adherence in p
Diab. (2014), http://dx.doi.org/10.1016/j.pcd.2014.03.001
almost all patients were adherent. In this study there was a
great discordance between results of the two study methods
which might be partly due to overestimated medication adher-
ence by the autocompliance method. Although self-reporting4 (1.6) 11 (4.3) 0.11
methods are considered as a convenient and cheap way to
assess medication adherence, review of prescription records
may lead to more  accurate results, but such a database was not
available for our population which may indicate that patients
over-report their adherence when using direct questions for
measuring compliance.
In comparison to other studies, Morris et al. found evi-
dence of poor adherence to insulin therapy among young
patients with type 1 diabetes. They noted that 28% of patients
obtained less insulin compared with their prescribed dose
according to pharmacy record data [10]. Similarly, results of
another study revealed that nearly one-third of prescribed
insulin doses were prepared by young patients with type 2 dia-
betes, and estimated adherence was 62–64% among patients
with type 2 diabetes [16]. In 2007, Donnelly et al. reported poor
adherence in 1099 patients with type 2 diabetes. Seven years
pharmacy record data revealed a 70.6% ± 17.7% mean adher-
ence to insulin among these patients. Patients with advanced
age, an older age at diagnosis, a lower BMI or who were more
socially active, had higher adherence [6]. Whereas, Cramer
et al. measured adherence using pharmacy records during the
2 year study period, results revealed good intentions to follow
the prescribed insulin regimen as patients used, on average,
77% of prescribed doses [9].
Findings of the current study are in line with those of Don-atients with diabetes: Risk factors for injection omission, Prim. Care
nelly et al. and indicate that participants with type 2 diabetes
have poor adherence. In contrast participants with type 1 dia-
betes had acceptable compliance.
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Table 3 – Association between potential barriers and insulin adherence in patients with type 1 diabetes.
Barrier Low adherence (n = 36) Intermediate to high adherence (n = 215) P-value
Sex, maleb 18 (50) 110 (51.2) 0.90
Age, yearsa 21.4 (9.6) 20.5  (10.0) 0.61
BMIa 23.3 (5.5) 21.2 (4.3) 0.01
Duration of diabetes, yearsa 6.7 (5.6) 8.5 (7.5) 0.24
Duration of insulin injection, yearsa 6.5 (5.6) 8.3 (7.4) 0.22
Educational statusb
Student 17 (47.2) 119 (56.1) 0.05
Under diploma 8 (22.2) 18 (8.5)
Diploma 8 (22.2) 39 (18.4)
University 3 (8.4) 36 (17.0)
Insulin daily dose, unita 50.7 (27.4) 43.7 (23.9) 0.11
Injection deviceb
Insulin pen 3 (8.3) 20 (9.3) 0.85
Syringe 33 (91.7) 195 (90.7)
Incapability for self injectionb 11 (30.6) 68 (31.6) 0.90
Number of daily injectionsb 0.37
1 2 (5.5) 11 (5.1) 0.47
2 28 (77.8) 121 (56.3)
≥3 6 (16.7) 83 (38.6)
Interference withb
Physical activities 13 (36.1) 81 (37.7) 0.90
Meal planning 10 (27.8) 43 (20.0) 0.29
Usual daily activities 9 (25.0) 29 (13.5) 0.08
Time consumingb 7 (19.4) 11 (5.1) <0.01
Difﬁculties with injectionb 5 (13.9) 18 (8.4) 0.30
Injection site painb 8 (22.2) 67 (31.2) 0.28
Embarrassmentb 3 (8.3) 1 (0.5) <0.01
Injection site reactionsb 16 (44.4) 104 (48.4) 0.66
Fear of hypoglycemiab 29 (80.6) 169 (78.6) 0.80
Belief in negative effects of insulin on
overall healthb
9 (25.0) 37 (17.2) 0.26
Feeling worse after insulin injectionb 5 (13.9) 1 (0.5) <0.01
Forgetfulnessb 7 (19.5) 10 (4.7) <0.01
Lack of enough injection instructionsb 3 (8.3) 10 (4.7) 0.36
Sick daysb 9 (25) 9 (4.2) <0.01
Polypharmacyb 1 (2.8) 6 (2.8) 0.99
Hypoglycemia episodesb 17 (47.2) 39 (18.1) <0.01
Costb 3 (8.3) 3 (1.4) 0.01
Weight gainb 2 (5.6) 0 (0.0) <0.01
Insulin shortageb 3 (8.3) 1 (0.5) <0.01
Difﬁculties in preparing injectionb 2 (5.6) 0 (0.0) <0.01
a Continuous variables are expressed as mean (SD).
b Categorical variables are expressed as n (%).
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tDemographic and disease characteristics of patients may
ave association with insulin omissions [8]. Results of this
ork indicate that the pattern might be different in patients
ith type 1 and type 2 diabetes. Patients with type 1 diabetes
re more  dependent on their care givers for insulin injections
nd also they were more  embarrassed regarding insulin injec-
ions, these were barriers that were more  frequently reported
y patients with type 1 diabetes than type 2. However in this
tudy, there was a signiﬁcant relationship between compli-
nce and embarrassment in both studied groups.
The emotional burden of injection may interfere with psy-
hological well-being. In a review of psychological barriers
o initiation and persistence with insulin therapy, differentPlease cite this article in press as: S. Farsaei, et al., Insulin adherence in p
Diab. (2014), http://dx.doi.org/10.1016/j.pcd.2014.03.001
trategies to decrease psychological insulin resistance have
een introduced [17]. Furthermore, interventions to improve
he relationship between health care providers and patientsseem to be beneﬁcial for overcoming psychological insulin bar-
riers [18] which need to be implemented in our health care
services.
Moreover, there are several device based strategies
to reduce embarrassment including insulin pens, which
could be considered to overcome this barrier to insulin
injections.
Because patients with type 1 diabetes are more  commonly
on intensive insulin injections, the number of daily insulin
injections was higher compared with patients with type 2
diabetes. Peyrot et al. showed more  frequent insulin omis-
sion among patients taking more  injections [8]. This could
indicate that the more  complex regimens are associated withatients with diabetes: Risk factors for injection omission, Prim. Care
lower levels of adherence. However, the number of daily injec-
tions was not signiﬁcantly related to adherence in our studied
population.
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Table 4 – Association between potential barriers and insulin adherence in patients with type 2 diabetes.
Barrier Low adherence (n = 74) Intermediate to high adherence (n = 183) P-value
Sex, Maleb 25 64 0.86
Age, years 55.9  (10.1) 55.1 (12.0) 0.60
BMIb 28.8 (4.8) 27.5 (4.8) 0.06
Duration of diabetes, yearsa 13.9 (7.8) 14.1 (8.3) 0.90
Duration of insulin injection,
yearsa
4.0 (4.1) 4.2 (4.8) 0.92
Educational statusb 0.47
Illiterate 16 (21.6) 39 (21.3)
Under diploma 41 (55.4) 87 (47.5)
Diploma 14 (18.9) 41 (22.4)
University 3 (4.1) 16 (8.7)
Insulin daily dose. unita 51.8 (26.7) 52.5 (28.6) 0.86
Injection deviceb 0.21
Insulin Pen 4 (5.4) 12 (6.6)
Syringe 70 (94.6) 164 (89.6)
Incapability for self injectionb 16 (21.6) 43 (23.5) 0.75
Number of daily injectionsb 0.60
1 6 (16.7) 22 (12.0)
2 55 (74.3) 126 (68.9)
≥3 13 (36.1) 35 (19.1)
Interference withb
Physical activities 30 (40.5) 62 (33.9) 0.31
Meal Planning 24 (33.8) 59 (32.2) 0.98
Usual daily activities 15 (20.3) 46 (25.1) 0.41
Time consumingb 15 (20.3) 17 (9.3) 0.02
Difﬁculties with injectionb 16 (21.6) 25 (13.7) 0.12
Injection site painb 13 (17.6) 55 (30.1) 0.04
Embarrassmentb 9 (12.2) 1 (0.5) <0.01
Injection site reactionsb 48 (64.9) 100 (54.6) 0.13
Fear of hypoglycemiab 60 (81.1) 132 (72.1) 0.14
Belief in negative effects of insulin
on overall healthb
30 (40.5) 53 (29.0) 0.07
Feeling worse after insulin
injectionb
14 (18.9) 4 (2.2) <0.01
Forgetfulnessb 30 (40.5) 6 (3.3) <0.01
Lack of enough injection
instructionsb
6 (8.1) 4 (2.2) 0.03
Sick daysb 22 (29.7) 21 (11.5) <0.01
Polypharmacyb 9 (12.2) 15 (8.2) 0.32
Hypoglycemia episodesb 42 (56.8) 31 (16.9) <0.01
Cost b 5 (6.8) 2 (1.1) 0.01
Weight gainb 8 (10.8) 2 (1.1) <0.01
Insulin shortage b 9 (12.2) 2 (1.1) <0.01
Difﬁculties in preparing injectionb 4 (5.4) 1 (0.5) 0.01
a Continuous variables are expressed as mean (SD).
b Categorical variables are expressed as n (%).
Patients with type 2 diabetes had more  complaints
regarding interference of insulin injections with their activ-
ities and meal planning which might be related to more  social
engagements and less ﬂexible lifestyle according to their age
group. Although these factors did not affect adherence sig-
niﬁcantly another study showed that interference with eating
and exercise played roles as barriers to insulin therapy [8].
Replacement of short acting regular insulin with rapid act-
ing insulin analogs is advisable in these patients and may
ameliorate their problem.
Use of multiple medications was another factor more  fre-Please cite this article in press as: S. Farsaei, et al., Insulin adherence in p
Diab. (2014), http://dx.doi.org/10.1016/j.pcd.2014.03.001
quently reported by type 2 patients as inﬂuencing insulin
omission than type 1 in our study. Multidrug regimens pro-
viding medical care to patients with type 2 diabetes mayhave negative impact on adherence [19]. Polypharmacy is
more  required in type 2 than type 1 patients to control other
metabolic risk factors such as hyperlipidemia and hyperten-
sion in addition to hyperglycemia [20] and may partly be
related to advanced age. However, in contrast to other reports,
polypharmacy was not signiﬁcantly associated with lower
adherence in our study.
Forgetfulness was raised more  by patients with type 2
diabetes, which could be frequent problems for their age
group. These patients were more  concerned regarding insulin
induced weight gain than the type 1 group, which may be dueatients with diabetes: Risk factors for injection omission, Prim. Care
to higher prevalence of obesity in this patient population. This
work also indicate that patients with type 2 diabetes are more
prone to stop insulin injections during illness than patients
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ith type 1 diabetes, which may be related to an underesti-
ation of the role of insulin by patients with type 2 diabetes
nd poor patient knowledge. These factors were associated
ith lower level of adherence.
In this study more  patients with type 2 diabetes declared
hat insulin injection had negative impact on their overall
ealth than type 1 diabetes, which needs to be managed by
ddressing the common misconceptions and negative atti-
udes regarding insulin therapy in educational programs and
ncorporating patient-centered treatment alliance in practice,
hich may improve health belief and attitude toward insulin
njection.
Despite ease of administration and dosing accuracy of
nsulin pens, in the studied population, minority of patients
9.1%) were using insulin pens which may be due to the
reat difference in medication cost compared to syringes. At
he time of the study, insulin pens were 15–20 times more
xpensive than insulin vials and pen devices were not under
edication insurance coverage, which had resulted in 45–60
imes more  out of pocket expenses.
There are piles of evidence which support the advantages
f pen devices over syringes for improving insulin adherence,
hich in most cases simultaneous reduction in healthcare
tilization and overall treatment costs has been reported [21].
In this study medication cost had a signiﬁcant relation-
hip with low compliance, which is in line with other reports
n patients with diabetes [22–24]. Although at time of the
resent study insurance companies covered 70% of the cost of
nsulin vials, still medication cost was considered as a barrier
o insulin injections. In order to address this barrier, pres-
ure of ﬁnancial barriers should be buffered by changing the
nsurance schemes to reduce patient co-payments [25]. More-
ver, some studies indicate that addressing non-cost barriers
o adherence may also decrease the tendency to medication
nderuse while encountering cost related problems [26,27].
In the current study patients with type 1 and type 2 diabetes
ith lower adherence had experienced more  hypoglycemic
pisodes and were more  concerned about weight gain.
We noted that almost all patients periodically missed
oses as they were concerned about the possibility of insulin
nduced hypoglycemia. This was associated with an overall
ower adherence and has been reported previously by Peyrot
t al. [28]. Other studies also reported that patients with dia-
etes on insulin therapy who experienced hypoglycemia had
ower adherence because they had experienced an unpleasant
r dangerous situation that had changed their behaviors [29].
Moreover, speciﬁc risk factors for the development of hypo-
lycemia should be addressed in individuals. Hypoglycemia
wareness and management should be considered as part
f educational programs for patients and caregivers. In cor-
oboration, some studies have indicated that educational
rograms can signiﬁcantly reduce the risk of severe hypo-
lycemia [30,31]. Additionally, behavioral interventions that
ocus on habituation may be beneﬁcial adjuncts to educa-
ional strategies to prevent hypoglycemia. Besides, changing
o insulin analogs may also reduce hypoglycemia risk. SincePlease cite this article in press as: S. Farsaei, et al., Insulin adherence in p
Diab. (2014), http://dx.doi.org/10.1016/j.pcd.2014.03.001
nsulin analogs in our country are exclusively available as pen
evices, results of the present study indicate under usage of
hese insulins in our population, which could be mainly due
o the high cost of insulin analogs. x x ( 2 0 1 4 ) xxx–xxx 7
To manage weight gain problem, some patients intention-
ally omit their insulin injections as a weight management plan
[32]. A well-integrated health system is needed to incorpo-
rate a customized program of medical nutrition therapy and
physical activity in therapeutic strategies.
Forgetfulness and insulin omission during sick days were
more  common in patients with low compliance.
This may reﬂect that future interventions should also
focus on family support, reminder systems and telemedicine.
Increasing awareness through patient education and family
engagement in implementation of speciﬁc measures to tar-
get insulin injection barriers may be associated with higher
adherence among patients with diabetes.
In one study, pain and embarrassment associated with
insulin injection resulted in insulin omission but skin bruis-
ing, dissatisfaction with time needed for injection, and ease
of insulin use did not affect insulin therapy [8]. This study
suggests that dissatisfaction with time needed for injection,
embarrassment, and difﬁculties in preparing injections was
associated with lower adherence in patients with both type 1
and type 2 diabetes, which could all be mitigated by changing
to insulin pens.
Injection site pain and lack of enough injection instructions
had a statistically signiﬁcant relationship with lower adher-
ence exclusively in patients with type 2 diabetes. This might
reﬂect the requirement for reinforced injection instructions in
patients with type 2 diabetes probably due to their age group.
On the other hand, moderate to high adherent patients
with type 1 diabetes had higher educational attainment com-
pared to low adherence patients. It shows that planning
strategies to improve adherence should be intensiﬁed for
patients educated to a lower level.
In the current study, insulin persistence was more  com-
mon in adherent patients which may indicate that barriers
are common to both practices.
Considering factors inﬂuencing skipping insulin doses
could be helpful to plan proper strategies to improve adher-
ence among patients with diabetes.
A large sample of patients with diabetes mellitus was
recruited in this study, however, more  adherent patients might
have been more  interested to be involved in this study and
therefore we may have overestimated adherence. In this study
objective methods for measurement of insulin use such as
reﬁll data were not used. Therefore, patients might have
perceived themselves more  adherent compared to other stud-
ies measuring adherence by reﬁll data. Moreover, we  did not
evaluate the correlation between adherence and HbA1c and
health outcome.
In conclusion, there is no single solution to overcome com-
pliance barriers in our studied population, but results indicate
that changing to insulin pens might alleviate most of detected
barriers and signiﬁcantly improve patient compliance.
Recently insulin pens have become under the coverage
of insurance companies in our country and authors of the
present study are assessing its effect on patients’ compliance.atients with diabetes: Risk factors for injection omission, Prim. Care
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